FY2016 EPS Estimates for Immune Design Corp. (IMDZ) Boosted by Jefferies Group
Immune Design Corp. (NASDAQ:IMDZ) – Jefferies Group upped their FY2016 EPS estimates for Immune Design Corp. in a research report issued on Wednesday. Jefferies Group analyst B. Abrahams now anticipates that the firm will post earnings of ($2.44) per share for the year, up from their prior estimate of ($2.67). Jefferies Group has a “Buy” rating and a $15.00 price target on the stock. Jefferies Group also issued estimates for Immune Design Corp.’s Q4 2016 earnings at ($0.54) EPS, FY2017 earnings at ($2.55) EPS, FY2018 earnings at ($2.75) EPS, FY2019 earnings at ($0.40) EPS and FY2020 earnings at ($1.41) EPS.
Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, November 9th. The company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.11. Immune Design Corp. had a negative return on equity of 50.92% and a negative net margin of 415.05%. The company earned $8.20 million during the quarter, compared to analyst estimates of $1.73 million.
Other research analysts have also recently issued reports about the company. Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research report on Sunday. Zacks Investment Research raised Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Friday, August 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $13.50.
Immune Design Corp. (NASDAQ:IMDZ) opened at 8.30 on Monday. The stock’s market cap is $210.89 million. Immune Design Corp. has a one year low of $4.50 and a one year high of $23.55. The stock’s 50 day moving average price is $6.97 and its 200 day moving average price is $8.63.
In related news, Director Lewis W. Coleman acquired 40,000 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The shares were purchased at an average price of $6.25 per share, with a total value of $250,000.00. Following the completion of the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at $312,500. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Group L. P. Column acquired 800,000 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The stock was bought at an average cost of $6.25 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here. 42.90% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank increased its position in Immune Design Corp. by 14.7% in the second quarter. Swiss National Bank now owns 12,500 shares of the company’s stock valued at $102,000 after buying an additional 1,600 shares during the period. ProShare Advisors LLC increased its position in Immune Design Corp. by 1.1% in the second quarter. ProShare Advisors LLC now owns 16,372 shares of the company’s stock valued at $134,000 after buying an additional 185 shares during the period. Highbridge Capital Management LLC bought a new position in Immune Design Corp. during the second quarter valued at approximately $215,000. California State Teachers Retirement System increased its position in Immune Design Corp. by 25.1% in the third quarter. California State Teachers Retirement System now owns 29,374 shares of the company’s stock valued at $223,000 after buying an additional 5,900 shares during the period. Finally, Alps Advisors Inc. increased its position in Immune Design Corp. by 25.0% in the second quarter. Alps Advisors Inc. now owns 28,310 shares of the company’s stock valued at $231,000 after buying an additional 5,657 shares during the period. 47.66% of the stock is currently owned by hedge funds and other institutional investors.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.
Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.